IBI Board of Directors

David A. Yost, Ph.D. — President and CEO of Innovative Biosensors, Inc.

John de Koning, Ph.D. — Partner, LSP (Life Sciences Partners)
John de Koning, Ph.D., is partner at LSP. John currently serves on the supervisory boards of Pronota, Skyline Diagnostics, arGEN-X, Merus and Innovative Biosensors Inc and has a board observer position at Prosensa. From 2001 to 2005, John was at Semaia Pharmaceuticals, a portfolio company of LSP. In 2003, Semaia Pharmaceuticals was acquired by Hybrigenics, where John set up Target Discovery and became Managing Director of Semaia. In addition, he was a member of the management team responsible for technology transfer at a large oncology consortium of leading Dutch scientists funded by the Dutch government, called the Cancer Genomics Center, a center of excellence of the Netherlands Genomics Initiative. John has a Masters degree in molecular biology from the University of Utrecht, The Netherlands and a Ph.D. in oncology from the Erasmus University of Rotterdam, The Netherlands. After his PhD, John received a prestigious fellowship from the Dutch Cancer Society to work at the UCSF Cancer Center in San Francisco. His results were published in numerous leading scientific journals, including Nature Genetics. In addition to these achievements, John is inventor on several patents.

William W. Brooke — Executive Vice President, Harbert Management Corporation; Managing Partner, Harbert Venture Partners, LLC
Mr. Brooke is Executive Vice President of Harbert Management Corporation and Managing Partner of Harbert Venture Partners. He is also a Partner of the Harbinger/Aurora Venture Funds and serves on their Investment Committee and Members' Advisory Committee. He has been advising start-up companies for more than twenty years, and has also served on the boards of AV Holdings (Atherotech), Visador, Nationwide Homes, Emageon and Maxcyte.

As Executive Vice President and Board member of Harbert for nearly fifteen years, Mr. Brooke initially served as the Firm's General Counsel and later as its Chief Operating Officer. Before joining Harbert in 1991, he was founder and managing partner of Wallace, Jordan, Ratliff and Brandt, a law firm in Birmingham, AL.

Mr. Brooke is a guest lecturer on venture capital for the MBA programs at the University of Alabama and the University of Alabama in Birmingham and currently serves as Chairman of the Southeast Life Sciences Association. He holds a degree in law (J.D.) and a Bachelor of Science in Business Management from the University of Alabama.

Mark Grovic — Founding Partner and Managing Director, New Markets Growth Fund
Mr. Grovic is a Founding Partner and Managing Director of the New Markets Growth Fund (NMGF). Mr. Grovic serves on the Board of Directors of Innovative Biosensors, Lightningcast, and Artifact Software and is a board observer for BioSET and BDMetrics.

Prior to co-founding the NMGF, Mr. Grovic was with Small Enterprise Assistance Funds (SEAF) as its Portfolio Manager. Mr. Grovic was based in Tallinn, Estonia, from 1997 to 1999 as Director of the Baltic Small Equity Fund, managed by SEAF, where he sat on the Board for ten portfolio companies in industries that included biotechnology and medical equipment.

From 1995 to 1997, Mr. Grovic was Co-Founder of the Templeton Emerging Europe Fund, a $60 million Central European private equity fund, and a Principal of the Fund Manager, Templeton Direct Advisors, a wholly owned direct investment subsidiary of the Franklin Templeton Group.

Mr. Grovic received his B.A. from the University of California, Berkeley, and his J.D. from Georgetown University. He has graduate work in accounting and finance at George Washington University and Pace University.

Joseph Del Guercio — Principal, CNF Investments
Prior to joining CEI, Mr. Del Guercio was at LPL Financial Services, a Boston and San Diego based independent broker dealer, where he
was responsible for strategic planning, new product development, and acquisitions. Prior to LPL, Mr. Del Guercio was at Robertson Stephens and Goldman Sachs, where he focused on mergers and acquisitions, private and public equity financings, and restructurings. Mr. Del Guercio serves on the Board of Ecutel Systems, Vital Sensors, Verax Biomedical, and Alfred Street Partners. Mr. Del Guercio is also a Board Observer with Lipomics Technologies and Overture Technologies. Mr. Del Guercio has an M.B.A. from Harvard Business School and a B.S. from Boston College.

Cole Van Nice — Partner, Chart Venture Partners
Mr. Van Nice is a Partner at Chart Venture Partners, an early-stage technology venture capital fund focused on homeland defense and security sectors. He joined Chart in 2006 after a decade of experience in international venture capital, private equity, and investment banking. He was previously Vice President of Darby Overseas Investments, the global Emerging Markets private equity and venture capital arm of Franklin Templeton, where he co-founded the firm's technology venture capital business and contributed to the firm's growth in AUM from $250 million to over $1.2 billion. From 2001-2006, Mr. Van Nice co-led Darby's early-stage investment activity with a special focus on Brazil and China, and served on the Board of Directors of several successful technology start-ups. Prior to Darby, Mr. Van Nice worked in investment banking and equity research, focusing on international telecommunications, media, and technology sectors for Santander Investment Securities Inc. Mr. Van Nice holds a B.A. from Washington and Lee University and is a CFA charterholder.

Dr. Caroline Popper — President and Co-founder, Popper and Co.
Dr. Caroline Popper, a bioscience executive, was appointed to the board in December 2007. Caroline, the president and co-founder of Popper and Company, has 17 years of hands-on biotech/life sciences operating experience. An internist and pathologist, she combines this perspective with that gained from managing a wide spectrum of life sciences businesses in diagnostics, devices and drug discovery. Her business management experience in both Fortune 500 and start-up settings and extensive track record creating strategic and business partnerships in the biotech arena is key to the perspective she provides to her clients. In a 10-year career at Becton Dickinson (NYSE: BDX), Caroline’s global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding General Manager of BDGene; a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. From 2000 to 2002, she was the Chief Business Officer for MDS Proteomics, a drug discovery company with operations in the US, Canada and Europe.